Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

QTc Interval Prolongation with Psychiatric Medications

Understanding QT vs QTc Interval

  • The European Society of Cardiology recommends using the QTc interval, which corrects the raw QT interval for heart rate variations, as the clinically relevant measurement for assessing arrhythmia risk with psychiatric medications 1
  • The QT interval is the raw measurement on ECG from the beginning of the QRS complex to the end of the T wave, representing ventricular depolarization and repolarization 1
  • Two main formulas are used for QT correction: Bazett's formula and Fridericia's formula, with Fridericia's formula recommended especially at high heart rates 1

Clinical Significance of QTc vs QT

  • The European Heart Rhythm Association recommends using QTc as the preferred measurement for clinical decision-making, as it allows standardized assessment regardless of heart rate 1, 2
  • Normal upper QTc values are 450 ms in men, 460 ms in women, and 440 ms in children, according to the European Society of Cardiology 1
  • QTc values from 440-470 ms are considered a "grey zone" due to overlap between affected individuals and controls, as reported by the European Heart Journal 1
  • Clinical guidelines use QTc thresholds for safety monitoring, with QTc >500 ms or increase >60 ms from baseline requiring dose reduction or medication discontinuation, as recommended by the European Society of Cardiology 1, 2

Psychiatric Medications and QT/QTc Prolongation

  • Tricyclic antidepressants (TCAs) prolong QTc interval and increase risk of cardiac arrest (OR=1.69), according to the European Heart Journal 3, 4
  • Methadone causes pronounced QTc prolongation with several reported cases of Torsades de Pointes, as reported by the European Heart Journal 3

Risk Factors for QTc Prolongation

  • Female gender increases risk, as reported by the European Society of Cardiology 5
  • Electrolyte abnormalities, especially hypokalemia and hypomagnesemia, increase risk, according to the European Heart Journal 1, 5
  • Concomitant use of multiple QT-prolonging medications increases risk, as reported by the European Heart Journal 1, 4

Monitoring Recommendations

  • ECG should be evaluated before initiation of treatment and during dose titration of QT-prolonging medications, as recommended by the European Society of Cardiology 1
  • If QTc reaches >500 ms or increases by >60 ms from baseline, treatment should be discontinued or dose reduced, according to the European Heart Journal 1, 2
  • Automated QT interval measurements are acceptable only if the ECG is otherwise normal; manual measurement is recommended in clinical practice, as reported by the European Heart Journal 1